ES2721916T3 - Composición oral sólida que contiene colorantes para uso en diagnóstico endoscópico - Google Patents

Composición oral sólida que contiene colorantes para uso en diagnóstico endoscópico Download PDF

Info

Publication number
ES2721916T3
ES2721916T3 ES13774382T ES13774382T ES2721916T3 ES 2721916 T3 ES2721916 T3 ES 2721916T3 ES 13774382 T ES13774382 T ES 13774382T ES 13774382 T ES13774382 T ES 13774382T ES 2721916 T3 ES2721916 T3 ES 2721916T3
Authority
ES
Spain
Prior art keywords
dye
unit doses
weight
matrix
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13774382T
Other languages
English (en)
Inventor
Luigi Moro
Alessandro Repici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Application granted granted Critical
Publication of ES2721916T3 publication Critical patent/ES2721916T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/006Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/003Thiazine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A61K49/0086Polymersome, i.e. liposome with polymerisable or polymerized bilayered-forming substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089Particulate, powder, adsorbate, bead, sphere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición sólida que contiene al menos un colorante junto con al menos un excipiente fisiológicamente aceptable que comprende: a) una matriz que comprende compuestos lipófilos con un punto de fusión por debajo de 90 °C, y opcionalmente compuestos anfifílicos, en la que dicho al menos un colorante está incorporado al menos parcialmente, b) una matriz externa que comprende compuestos hidrófilos, en la que la matriz lipófila, y opcionalmente la matriz anfifílica están dispersas; c) opcionalmente otros excipientes fisiológicamente aceptables; d) un recubrimiento gastrorresistente opcional para el uso en el estudio endoscópico, caracterizada porque se administran de manera oral cuatro, seis u ocho dosis unitarias de la misma a un ser humano, en la que se administra una cantidad total de 100 a 200 mg de dicho al menos un colorante a dicho ser humano en las 48 horas antes del estudio endoscópico; en la que ocho dosis unitarias de la misma, que contienen cada una 25 mg en peso de dicho al menos un colorante, o en la que cuatro dosis unitarias de la misma, que contienen cada una 50 mg en peso de dicho al menos un colorante, o en la que seis dosis unitarias de la misma, que contienen cada una 25 mg en peso de dicho al menos un colorante, o en la que cuatro dosis unitarias de la misma, que contienen cada una 25 mg en peso de dicho al menos un colorante se administran a dicho ser humano antes del estudio endoscópico; y en la que dicho al menos un colorante es azul de metileno.
ES13774382T 2012-10-19 2013-09-26 Composición oral sólida que contiene colorantes para uso en diagnóstico endoscópico Active ES2721916T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715981P 2012-10-19 2012-10-19
EP12189206.1A EP2722058A1 (en) 2012-10-19 2012-10-19 Solid oral composition containing dyes for use in endoscopic diagnosis
PCT/EP2013/070060 WO2014060199A1 (en) 2012-10-19 2013-09-26 Solid oral composition containing dyes for use in endoscopic diagnosis

Publications (1)

Publication Number Publication Date
ES2721916T3 true ES2721916T3 (es) 2019-08-06

Family

ID=47137560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13774382T Active ES2721916T3 (es) 2012-10-19 2013-09-26 Composición oral sólida que contiene colorantes para uso en diagnóstico endoscópico

Country Status (27)

Country Link
US (3) US20150283268A1 (es)
EP (3) EP2722058A1 (es)
JP (1) JP6267210B2 (es)
KR (1) KR102207507B1 (es)
CN (3) CN104755107A (es)
AR (1) AR091984A1 (es)
AU (1) AU2013331964B2 (es)
BR (1) BR112015008772A2 (es)
CA (1) CA2886201C (es)
DK (1) DK2908866T3 (es)
ES (1) ES2721916T3 (es)
HK (1) HK1211465A1 (es)
HR (1) HRP20190710T1 (es)
HU (1) HUE043112T2 (es)
IL (1) IL237907A (es)
IN (1) IN2015DN02818A (es)
LT (1) LT2908866T (es)
MX (1) MX361737B (es)
NZ (1) NZ706363A (es)
PL (1) PL2908866T3 (es)
PT (1) PT2908866T (es)
RS (1) RS59152B1 (es)
RU (1) RU2649783C2 (es)
TR (1) TR201905800T4 (es)
TW (1) TWI651102B (es)
WO (1) WO2014060199A1 (es)
ZA (1) ZA201502370B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017364274A1 (en) * 2016-11-28 2019-05-30 Cosmo Technologies Ltd. Solid oral composition containing dyes
IT201900003113A1 (it) * 2019-03-04 2020-09-04 Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologna Bevanda coadiuvante

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2129273C1 (ru) * 1997-11-26 1999-04-20 Московский научно-исследовательский онкологический институт им.П.А.Герцена Способ эндоскопической флюоресцентной диагностики злокачественных опухолей полых органов
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
TR200200562T2 (tr) 1999-06-14 2002-05-21 Cosmo S.P.A Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
US7230088B2 (en) * 2001-07-03 2007-06-12 Mallinckrodt, Inc. Compounds for dual photodiagnosis and therapy
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
RU2253350C2 (ru) * 2003-06-30 2005-06-10 Государственное учреждение здравоохранения Иркутский Областной Диагностический Центр Способ эндоскопического исследования желудка
US20050244368A1 (en) * 2004-04-29 2005-11-03 Pashankar Dinesh S Pre-endoscopic use of polyethylene glycol compositions
US20070077202A1 (en) * 2005-06-12 2007-04-05 Pentax Corporation Histostain composition for endoscope
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa

Also Published As

Publication number Publication date
EP2722058A1 (en) 2014-04-23
RU2015118584A (ru) 2016-12-10
WO2014060199A1 (en) 2014-04-24
TW201420131A (zh) 2014-06-01
CN112891563A (zh) 2021-06-04
JP2015534956A (ja) 2015-12-07
EP2908866B1 (en) 2019-02-27
ZA201502370B (en) 2016-11-30
DK2908866T3 (da) 2019-05-06
MX361737B (es) 2018-12-14
RS59152B1 (sr) 2019-10-31
HRP20190710T1 (hr) 2019-08-23
CA2886201A1 (en) 2014-04-24
US20200129643A1 (en) 2020-04-30
AU2013331964B2 (en) 2018-03-29
MX2015004935A (es) 2015-12-01
KR20150068412A (ko) 2015-06-19
EP2908866A1 (en) 2015-08-26
JP6267210B2 (ja) 2018-01-24
IN2015DN02818A (es) 2015-09-11
AR091984A1 (es) 2015-03-18
HK1211465A1 (en) 2016-05-27
CN117462704A (zh) 2024-01-30
RU2649783C2 (ru) 2018-04-04
CA2886201C (en) 2021-03-23
KR102207507B1 (ko) 2021-01-27
IL237907A (en) 2017-06-29
US20150283268A1 (en) 2015-10-08
AU2013331964A1 (en) 2015-04-09
NZ706363A (en) 2019-03-29
PT2908866T (pt) 2019-05-24
US20230130628A1 (en) 2023-04-27
LT2908866T (lt) 2019-06-10
TWI651102B (zh) 2019-02-21
PL2908866T3 (pl) 2019-10-31
EP3650048A1 (en) 2020-05-13
TR201905800T4 (tr) 2019-05-21
HUE043112T2 (hu) 2019-08-28
CN104755107A (zh) 2015-07-01
BR112015008772A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2011002255A1 (es) Compuestos derivados de 2-acetamino-5-aril-(1,2,4-triazolona o imidazolona), antagonista del receptor v1a y v2; composicion farmaceutica que los comprende; procedimiento de preparacion; y su uso en el tratamiento de insuficiencia cardiaca, hiponatremia hipervolemica y euvolemica, ascitis, ademas, entre otras.
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CL2007001870A1 (es) Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
IT1398643B1 (it) Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
AR069211A1 (es) Derivados de acidos de 1,2,4-oxadiazol ciclobutanoamino carboxilicos, una composicion farmaceutica, proceso de preparacion del compuesto y su uso para preparar medicamentos
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
AR108231A1 (es) Composiciones farmacéuticas orales de mesalazina
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
BR112015007592A2 (pt) composições de enalapril
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
ES2721916T3 (es) Composición oral sólida que contiene colorantes para uso en diagnóstico endoscópico
ES2637392T3 (es) Composiciones para el tratamiento o prevención del cáncer de próstata a base de extracto de semillas de brócoli
PE20091900A1 (es) Una formulacion farmaceutica solida
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
CR20190203A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina